Clinical Trials Browser

Interventional × bemarituzumab × 1 year × Clear all

NCT05052801 2026-05-27

FORTITUDE-101

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT07146919 2026-04-23

ANGELICA

Phase 1/2 Withdrawn

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT05325866 2026-02-04

FORTITUDE-301

Phase 1/2 Completed

BreastGastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06967987 2026-01-21

BEMAFLOT

Phase 2 Withdrawn

Adenocarcinoma

NCT05111626 2025-12-15

FORTITUDE-102

Phase 3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Phase 1/2 Active not recruiting

Gastrointestinal

Stomach Neoplasms